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Abstract
FUS/TLS is a nucleic acid binding protein that, when mutated, can cause a subset of familial amyotrophic lateral sclerosis
(fALS). Although FUS/TLS is normally located predominantly in the nucleus, the pathogenic mutant forms of FUS/TLS traffic
to, and form inclusions in, the cytoplasm of affected spinal motor neurons or glia. Here we report a yeast model of human
FUS/TLS expression that recapitulates multiple salient features of the pathology of the disease-causing mutant proteins,
including nuclear to cytoplasmic translocation, inclusion formation, and cytotoxicity. Protein domain analysis indicates that
the carboxyl-terminus of FUS/TLS, where most of the ALS-associated mutations are clustered, is required but not sufficient
for the toxicity of the protein. A genome-wide genetic screen using a yeast over-expression library identified five yeast DNA/
RNA binding proteins, encoded by the yeast genes ECM32, NAM8, SBP1, SKO1, and VHR1, that rescue the toxicity of human
FUS/TLS without changing its expression level, cytoplasmic translocation, or inclusion formation. Furthermore, hUPF1,a
human homologue of ECM32, also rescues the toxicity of FUS/TLS in this model, validating the yeast model and implicating
a possible insufficiency in RNA processing or the RNA quality control machinery in the mechanism of FUS/TLS mediated
toxicity. Examination of the effect of FUS/TLS expression on the decay of selected mRNAs in yeast indicates that the
nonsense-mediated decay pathway is probably not the major determinant of either toxicity or suppression.
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Introduction
Amyotrophic lateral sclerosis (ALS, also called Lou Gehrig’s
disease after one of its most famous victims) is a relentlessly
progressive, fatal neurodegenerative disease with a prevalence of
,5 people out of 100,000 each year and an average age of onset of
,60 years. Patients with ALS suffer from degeneration of motor
neurons in the brain and spinal cord, which leads to progressive
muscular weakness. ALS accounts for ,1/300 to 1/400 of all
deaths, which means that about 1,000,000 people now alive in the
United States will develop ALS. Death typically occurs 3–5 years
after disease onset, due to respiratory paralysis. There is no
effective treatment for the disease; the only approved ALS drug
(riluzole) extends the lifespan of some ALS patients by only about 3
months.
While most forms of ALS are sporadic and idiopathic (sALS),
,10% of cases are inherited in a Mendelian fashion and are
designated familial ALS (fALS). As is the case for Parkinson’s and
Alzheimer’s diseases, which also have ,10% familial forms,
genetic analysis has identified several genes that cause fALS. The
first mutations were identified in SOD1, which encodes the
ubiquitously expressed copper/zinc superoxide dismutase; these
variants cause ,20% of fALS worldwide. More than 150 different
ALS mutations, spanning virtually the entire coding sequence of
the highly conserved SOD1 gene, have been identified—nearly all
of them exhibiting autosomal dominant inheritance [1]. Although
inclusions containing aggregated SOD1 protein have been found
in the spinal motor neurons of patients with SOD1-dependent
fALS, they are generally not found in the sporadic disease.
More recently, other genes have been identified that collectively
account for a significant percentage of the remaining fALS cases.
These include the genes coding for alsin (ALS2), vesicle associated
membrane protein B (VAPB) [2], senataxin (SETX) [3], TAR-
DNA-binding protein (TDP-43) [4], fused in sarcoma or
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(OPTN) [7]. A small number of other genes have been associated
with increased risk for sALS, most recently ataxin-2 [8]. Studies of
these genes have provided important information about the
biochemical processes that may underlie ALS. Putative mecha-
nisms of toxicity targeting motor neurons include glutamate
excitotoxicity, oxidative damage, proteasome inhibition, mito-
chondrial dysfunction, ER stress, axonal transport defects, growth
factor signaling deficiency, and glial cell dysfunction [9,10].
Two of the genes associated with fALS, FUS/TLS and TDP-
43, are of special interest because inclusions containing these
proteins have been identified in motor neurons of both sporadic
and familial patients [11–15]. In addition, both of these genes have
been linked to rare forms of frontotemporal lobar degeneration
[16], indicating that they play crucial roles in other neurons. FUS/
TLS and TDP-43 are both predominantly nuclear RNA binding
proteins, although they have also been reported to bind DNA in
vitro. Both FUS/TLS and TDP-43 are believed to carry out
important functions in multiple steps of RNA processing, including
transcription, splicing, transport, translation, and decay [17]. The
finding that both are fALS genes (each accounts for about 5% of
familial ALS cases), and are involved in sALS, raises the possibility
that RNA processing or quality control (damage repair and decay
of prematurely terminated messages) may be central to ALS
pathology. However, the precise connections between RNA
biology and ALS remain to be discovered.
The FUS/TLS protein, which is ubiquitously expressed in all
tissues, contains an N-terminal putative transcriptional activation
domain (residues 1–267) rich in serine, tyrosine, glutamine, and
glycine residues, followed by a canonical RNA binding domain
(residues 285–371). The C-terminal region has a zinc finger
domain (residues 422–453) interrupting a long stretch rich in
arginines and glycines (residues 285–501). The extreme C-
terminal 25 amino acids (residues 501–526) also are rich in
arginines and glycines, and the majority of the ALS-associated
mutations are found among them. Among other postulated
functions, FUS/TLS is known to be a component of a large
nuclear ribonucleoprotein complex that functions in shuttling
mRNA out of the nucleus.
Variants of FUS/TLS have previously been studied for their
role in liposarcoma, in which the N-terminal transcriptional
activation domain of FUS/TLS is translocated into another
chromosomal locus, resulting in gene fusions and production of
chimeric oncoproteins (e.g. FUS-ERG, FUS-CHOP, and FUS-
CREB312). The fusion proteins are aberrant transcription factors
that contribute to the tumorigenic process by altering the
expression of many target genes [18].
Mutations in FUS/TLS found in fALS are largely clustered at
the extreme C-terminus of the protein. Postmortem histological
analysis from patients with FUS/TLS mutations indicates that the
normally nuclear protein is now found more predominantly in the
cytosol, where it forms punctate inclusions. This mislocalization/
inclusion-formation has been proposed to cause either a loss of
normal protein function in the nucleus, a gain of toxic function in
the cytosol, or both [5,17]. Recently, Dormann et al. [19] reported
that some of the disease-causing mutations affect a non-classical
PY nuclear localization signal (NLS) in the extreme C-terminus of
FUS/TLS and disrupt transportin-mediated nuclear import of the
protein. As a result, FUS/TLS distribution increases in the cytosol,
where the protein can be recruited into stress granules [20]. These
results have led to the hypothesis that nuclear import defects and
consequent cellular stress may be necessary, and possibly sufficient,
for FUS/TLS pathogenesis [19,20].
Since FUS/TLS-immunoreactive inclusions are reported to be
a common feature in both sporadic and familial ALS [13], it is
likely that an understanding of FUS/TLS-associated fALS could
also provide valuable information about the more common
sporadic form of the disease. Additionally, the involvement of
FUS/TLS in other neurodegenerative diseases, such as a subset of
FTLD (atypical FTLD-U) [21], neuronal intermediate filament
inclusion disease (NIFID) [22], and polyglutamine disease [23],
suggests that several neurodegenerative diseases may have similar
underlying pathogenic mechanisms. A better understanding of the
normal and aberrant functions of FUS/TLS might therefore
provide clues to uncovering the pathology of neurodegenerative
diseases beyond ALS. With this in mind, we set out to create a
model for FUS/TLS-dependent cytotoxicity in a genetically and
biochemically tractable organism.
With uniquely available genetic and biochemical tools, yeast has
proven to be a valuable system to study the functions of human
proteins involved in many diseases, including neurodegenerative
disorders [24–29]. Although yeast is a simple single-cell eukaryote,
many fundamental cellular processes are conserved between yeast
and higher eukaryotes, and a number were first discovered in S.
cerevisiae or its distant relative, S. pombe. If expression of FUS/TLS
in yeast can be shown to recapitulate some of the relevant features
of human FUS/TLS-dependent proteotoxicity, then genetic
screens can be used to dissect the pathways and processes involved.
In this article, we report a yeast model of FUS/TLS-dependent
cytotoxicity, in which over-expression and mislocalization of wild-
type or mutant FUS/TLS recapitulates the phenotypes of toxicity
and inclusion formation observed in the human disease. Certain
features of the model have allowed us to conclude that cytosolic
localization of large amounts of even the wild-type FUS protein is
sufficient to cause toxicity, supporting a hypothesis that had been
put forward based on studies in mammalian cells. A genetic screen
using this yeast model for suppressors of toxicity identifies, among
other genes, the yeast gene ECM32, an RNA helicase involved in
RNA quality control, as one that rescues FUS/TLS toxicity when
over-expressed. In addition, hUPF1, a human homolog of ECM32,
Author Summary
Of all the thousand natural shocks that flesh is heir to, one
of the most devastating is amyotrophic lateral sclerosis
(ALS), commonly known as Lou Gehrig’s Disease. This
disorder, which comes in both inherited and random
forms, is characterized by degeneration of spinal motor
neurons, leading to paralysis and death. The cause of the
sporadic form is unknown, but new insight has come from
studying the genetic variations that lead to the rarer
familial forms. One such gene, accounting for 5%–10% of
inherited ALS, is FUS/TLS, which encodes a protein that
normally lives in the nucleus of the cell and is involved in
the life-cycle of messenger RNA (mRNA). ALS-associated
mutations in FUS/TLS cause the protein to mislocalize
outside the nucleus into stress granules. Understanding
the basis for the toxicity of mislocalized FUS/TLS could lead
to new approaches to the treatment of ALS. We have
made a yeast model for FUS/TLS cellular toxicity that
recapitulates the mislocalization, granular accumulation,
and cell death. We have exploited the yeast model to
obtain information about what part of the protein is
required for proper localization and what part is essential
for toxicity. We have also identified several human genes
that, when over-expressed in yeast, are able to rescue the
cell from the toxicity of mislocalized FUS/TLS. These genes
all have functions in mRNA quality control, implicating
changes in this pathway in the pathology of ALS.
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and (to a lesser extent) hUPF3. The rescue does not involve a
decrease in FUS/TLS expression or a change in its localization or
inclusion formation, but it does depend on intact functional
domains of hUPF1. Since hUPF1 plays an important function in
mRNA quality control, our data raise the possibility that this
pathway might be involved in the pathogenesis of FUS/TLS-
associated ALS, and possibly of the disease in general. We have
investigated the role of one aspect of RNA quality control,
nonsense-mediated decay (NMD), using the yeast model but find
no evidence that NMD disruption is responsible for FUS/TLS
toxicity or that its upregulation is important for suppression.
Independently, Sun et al. (2010, [30]) have developed a similar
yeast model for FUS/TLS-associated ALS and have identified all of
the same suppressor genes, plus some additional ones, in a similar
screen. In addition, they have found genes that, when deleted,
modulate FUS/TLS toxicity in yeast, and have implicated stress
granules (discrete cytoplasmic phase-dense particles, observed in
cells exposed to heat, oxidative, hyperosmolarity, and UV stress,
where non-translating mRNAs are stored) in this process.
Results
Expression and Localization of Human FUS/TLS in Yeast:
Over-expression of FUS/TLS Is Toxic
Unlike wild type FUS/TLS, which is largely found in the
nucleus and somewhat diffusely in the cytosol, the mutant proteins
associated with fALS are predominantly aggregated in the
cytoplasm of neurons, where they are proposed to be toxic. To
determine whether the budding yeast S. cerevisiae may serve as a
model for investigating the molecular mechanisms of FUS/TLS
cytotoxicity, we generated yeast strains expressing FUS/TLS. The
human FUS/TLS gene, in both wild type and mutant (R521G and
H517Q) forms, was N-terminally fused to green fluorescent
protein (GFP) and placed under the control of the GAL1 promoter,
whereby expression is tightly controlled by switching the carbon
source in the medium. In these strains, expression of both WT and
mutant FUS/TLS is highly induced by shifting to galactose
medium. When either mutant or wild-type protein is over-
expressed (induced by 2% galactose), the majority of the protein
forms punctate aggregates in the cytosol (Figure 1A, and Figure
Figure 1. Expression, localization, and toxicity of FUS/TLS in yeast. (A) Cells expressing GFP or GFP-FUS were induced by 2% galactose for
6 h. Cells were then fixed and viewed by fluorescence microscopy. DAPI was used to stain the nucleus. (B) Yeast with integrated GFP, 1XFUS (1 copy
of untagged FUS integrated into the HIS3 locus in the genome), and 2XFUS (2 copies of untagged FUS integrated into the HIS3 locus and the TRP1
locus in the genome) were serially diluted (from left to right) and spotted onto plates containing either glucose (FUS expression ‘‘off’’) or galactose
(expression ‘‘on’’). Picture was taken after 2 d growth at 30uC.
doi:10.1371/journal.pbio.1001052.g001
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phenotype characteristic of FUS/TLS-associated sporadic and
familial ALS, as well as other neurodegenerative diseases [5]. Data
from an independent yeast model of FUS/TLS cytoxicity [30] and
expression of mutant forms of FUS/TLS in mammalian cells [20]
suggest that these aggregates could be localized to stress granules.
To test possible toxicity of aggregated FUS/TLS in the cytosol,
one copy of FUS/TLS (1XFUS; untagged) and two copies of
FUS/TLS (2XFUS; untagged) were integrated into the genome of
yeast strain W303a. Yeast strains with FUS/TLS (1XFUS and
2XFUS) were serially diluted and spotted onto plates with glucose
(expression repressed) and galactose (expression induced). As
shown in Figure 1B, FUS/TLS over-expression is toxic to yeast in
a dose-dependent manner under these proliferative growth
conditions, with the 2XFUS exhibiting greater toxicity than
1XFUS. Toxicity of the over-expressed mutant proteins was
comparable to that of the wild-type (Figure S1; see below for an
explanation), so the wild-type protein was used for most of the
remaining experiments, to avoid possible sequence-dependent
peculiarities.
Inclusions Formed by FUS/TLS Are Different from Those
Formed by PolyQ-Expanded Huntingtin
In yeast models for several other protein misfolding diseases,
although the morphologies of the aggregated proteins under the
fluorescence microscope look similar, the actual characteristics of
the aggregates are sometimes quite different. For example, yeast
toxicity and aggregation of the human Huntingon’s disease–
associated protein huntingtin harboring a pathogenic polygluta-
mine expansion (Htt103Q) can be rescued by the deletion of a heat
shock protein HSP104 (hsp104D) or yeast prion protein RNQ1
(rnq1D). However, the same deletions cannot rescue the cytosolic
aggregation and toxicity of TDP-43 in yeast [28]. Previous studies
also indicate that Htt103Q forms SDS-insoluble aggregates, which
cannot pass through a 0.2 mM cellulose acetate membrane;
however, TDP43 aggregates can pass freely [28].
FUS/TLS has been found to be associated with huntingtin
aggregates in Huntington’s disease patients [23], yet the
characteristics of FUS/TLS-dependent fALS resemble those of
TDP-43-associated ALS. To test possible differences between
FUS/TLS aggregates and huntingtin or TDP-43, FUS/TLS
aggregates isolated from over-expressing yeast were tested by a
filter retardation assay. As expected, Htt103Q was trapped by the
membrane; however, FUS/TLS aggregates, like TDP43, passed
through the membrane freely (Figure 2A). Consistent with this
observation, unlike their effects on Htt103Q, deletion of HSP104
and RNQ1 did not modify the toxicity of FUS/TLS in yeast
(Figure 2B), nor its aggregation or localization (Figure 2C). In
addition, over-expression of HSP104 and RNQ1 had no effect on
FUS/TLS toxicity either (unpublished data).
Figure 2. Aggregates of FUS/TLS are different from that of Huntingtin. (A) Yeast cells containing GFP-tagged N-terminal huntingtin
harboring pathogenic polyglutamine expansions (Htt103Q, stretch of 103 consecutive glutamines), normal huntingtin (Htt25Q, stretch of 25
consecutive glutamines), and GFP tagged FUS/TLS were induced with galactose for 6 h. Filter retardation assay was performed to characterize the
aggregates. (B) GFP tagged FUS, Htt103Q, or Htt25Q was transformed into HSP104D, RNQ1D deletion strains and the isogenic wild type strain BY4743
(WT). Cells were serially diluted and spotted onto glucose (expression ‘‘off’’) or galactose plate (expression ‘‘on’’) to observe toxicity. Pictures were
taken after 2 d growth at 30uC. GFP on the same vector (GFP) was used as control. (C) The same strains as above were visualized for localization and
aggregation of the proteins by fluorescence microscopy. (D) pYES2CT/GFP-FUS (FUS) and empty vector (Vec) were transformed into wild type yeast,
and yeast containing integrated Htt103Q. Freshly grown cells were then serially diluted and spotted onto glucose (expression ‘‘off’’) or galactose
plate (expression ‘‘on’’) to observe toxicity. Pictures were taken after 2 d growth at 30uC.
doi:10.1371/journal.pbio.1001052.g002
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suggest that the toxicity mechanism underlying these two proteins
might be different. Consistent with this, toxicity resulting from the
over-expression of FUS/TLS and Htt103Q is additive (Figure 2D).
The C-Terminal Domain of FUS/TLS Is Necessary But Not
Sufficient for Its Toxicity
The full-length FUS/TLS protein has an N-terminal transcrip-
tional activation domain (residues 1–267) including SYQG-rich
(residues 1–164) and G-rich (residues 165–267) subdomains, and a
C-terminal RNA binding region (residues 285–526) including
RNA binding (residues 285–370), Zinc Finger (residues 422–452),
and RGG-rich domains (residues 371–421 and 453–501)
(Figure 3A). The extreme C-terminus (residues 511–526) contains
an arginine-rich sequence and a putative nuclear localization
signal [19]; every one of the arginines in this region is the site of an
ALS-associated mutation. To pinpoint which part of FUS/TLS is
required for its toxicity in yeast, we characterized eight fragments
of the wild-type FUS/TLS protein (tagged with GFP at the N-
terminus) for their localization, aggregation, and toxicity. As
shown in Figure 3B, after removal of the C-terminal region of the
protein (constructs 1 [residues 1–164], 2 [residues 1–267], and 3
[residues 1–370]), the protein is no longer toxic, suggesting that the
C-terminal domain from residues 371 on is required for toxicity.
However, expression of the C-terminal domain only (constructs 6
[residues 165–526], 7 [residues 268–526], and 8 [residues 371–
526]) is not toxic, indicating that both C- and N-terminal regions
of the protein are essential for toxicity.
To check for a possible correlation between toxicity and
aggregation, all eight proteins (N-terminally GFP tagged) were
checked using fluorescence microscopy. As shown in Figure 3C, all
the proteins, when over-expressed, show aggregation; however,
only constructs 4 (which lacks the extreme C-terminal 15 residues)
and 5 (the full-length protein) are toxic. Interestingly, the
aggregates formed by constructs 4 and 5 appear slightly different
from each other and also may differ from the aggregates formed
by the other constructs. These data suggest that toxicity of FUS/
TLS in yeast involves mechanisms beyond protein aggregation, a
hypothesis supported by the results of the suppressor screen (see
below).
To test the possible effects of the GFP tag on toxicity, we
expressed constructs 3–5 without the N-terminal GFP fusion.
Figure 3. Toxicity and localization of individual domains of FUS/TLS. (A) A serial deletion of the full length FUS/TLS gene from c-terminus,
labeled as 1–4, and from N-terminus, labeled as 6–8, was carried out. (B) The truncated genes (with GFP tag at N-terminus) were then placed under
the control of GAL1 promoter on the yeast expression vector pYES2CT. Yeast with above constructs was serially diluted and spotted onto plate
containing either glucose (expression ‘‘off’’) or galactose (expression ‘‘on’’). Pictures of the plates were taken after 2 d growth at 30uC. (C) Cells
containing the above constructs were grown in the Ura-Raffinose medium to mid-log phase. Expression of the proteins was induced by 2% galactose
for 6 h. Localization and aggregation of the proteins was visualized by fluorescence microscopy. (D) Constructs 3–5 as shown in (A) were also cloned
into yeast expression vector pDEST52 without the GFP tag. Yeast containing the constructs was serially diluted and spotted onto glucose (expression
‘‘off’’) or galactose plate (expression ‘‘on’’). Picture of the plates was taken after 2 d growth at 30uC.
doi:10.1371/journal.pbio.1001052.g003
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the residues from 371 to 526, is not toxic, and constructs 4 and 5
are still toxic. Interestingly, the construct lacking the 15 amino
acids at the extreme C-terminal end (construct 4), where most of
the fALS mutations are clustered, is more toxic to yeast than the
full-length protein (construct 5). This result is consistent with the
recent finding that patients with a nonsense mutation of FUS/TLS
at position 495 have more rapidly progressive neurodegeneration
and earlier onset of the disease [20,31] and that the C-terminus
encodes a nuclear localization signal [19].
Localization and Toxicity of FUS/TLS in Yeast Is Not
Regulated by Either of the Major Yeast Arginine
Methyltransferases
Most mutations of FUS/TLS identified in fALS patients are
clustered at the very end of the C-terminus (residues 510–526), in a
region enriched with arginine residues [5]. At least one disease-
causing mutation has been identified for each arginine in this
region, implying that these arginine residues play a critical role for
the function of the protein. One regulatory process involving
arginine residues is dimethylation, which is an important signal for
the nuclear/cytoplasmic translocalization of a series of RNA
binding proteins. That more than 20 arginine residues are indeed
dimethylated by the enzyme PRMT1 in FUS/TLS in mammalian
cells [32], and that all the known C-terminal region mutant forms
of FUS/TLS do translocate to the cytosol, together suggest that
arginine methylation may be involved in the shuttling of FUS/
TLS between nucleus and cytosol and thus may play a role in its
toxicity. To explore the possible role of the yeast arginine methyl
transferases in mislocalization, localization and toxicity of FUS/
TLS was studied in yeast strains in which each of the two major
yeast arginine methyltransferases were deleted (rmt1D and rmt2D).
As shown in Figure 4, FUS/TLS is still toxic in rmt1D and rmt2D
strains (Figure 4A), and the protein is still aggregated in the cytosol
in both cases (Figure 4B).
To test the possible redundancy of arginine methyltransferase
activity in yeast, two small molecule compounds (AMI-1 and AMI-
4), previously shown to exhibit broad inhibition of arginine methyl
transferase activity in mammalian cells and in yeast [33], were
tested on the yeast strain over-expressing FUS/TLS. Consistent
with the results from the arginine methyl transferase deletion
study, inhibition of arginine methyl transferase by these two
compounds does not change FUS/TLS toxicity nor its localization
(unpublished data). In addition, over-expression of RMT1 and
RMT2, or of the human enzyme PRMT1, does not modify FUS/
TLS toxicity (unpublished data). These data suggest that at least
the predominant yeast arginine methyl transferases are not
involved in the cytotoxicity of FUS/TLS in yeast. We next
examined the possible role of nuclear localization signals in the
nuclear/cytosolic distribution of the human protein when
expressed in yeast.
The NLS of Human FUS/TLS Is Not Efficient in Yeast;
However, Cytosolic Localization Is Correlated with
Toxicity, Consistent with Findings for Neuronal Cells
It was recently reported that FUS/TLS carries a non-classical
PY nuclear localization signal (NLS) in its extreme C-terminus
(approx. residues 514–526) and this is necessary for its nuclear
import [19]. The disease-causing mutations clustered in this NLS
affect the nuclear localization of the protein. The toxicity of the
protein and the age of disease onset correlate with the protein’s
cytosolic mislocalization and aggregation [19,20,31]. Since wild-
type FUS was mostly aggregated in punctate granules in the yeast
cytosol, we posited that its NLS might not be functional in this
organism. If so, over-expression of even the wild-type protein
would recapitulate the toxicity of the human mutants, as observed,
through a failure in nuclear localization. To test this directly, we
compared the ability of the FUS NLS to direct nuclear localization
with a well-characterized yeast NLS that uses a similar PY
sequence (from Hrp1) by fusing them to GFP. Indeed the FUS
NLS was defective in nuclear localization (Figure 5A).
To determine if the failure in nuclear localization contributes to
toxicity, we tested two constructs, one in which the HRP1 NLS
was simply appended to the human protein (FUS_plus) and
another in which the HRP1 NLS was used to replace the FUS/
TLS (FUS_switch; Figure 5B). Both constructs dramatically
increased nuclear localization of FUS (Figure 5B) and both
reduced toxicity (Figure 5C). Aggregation was also reduced when
FUS was retargeted to the nucleus, but this is probably due to a
generally lower level of FUS expression in these constructs.
Toxicity was not completely ameliorated, likely because some
residual cytoplasmic FUS persisted even when augmented with the
HRP1 NLS (Figure 5B). This relationship between mislocalization
and toxicity is consistent with data from neuronal cells [19] and
suggests that the wild-type protein is toxic in yeast because the
nonfunctional NLS mimics the mislocalization effect of the
disease-producing mutations in human cells.
Genome Wide Screen to Identify Genes Whose Over-
expression Rescues the Toxicity of FUS/TLS in Yeast
The ability of yeast expressing human FUS/TLS to recapitulate
several salient features of disease prompted us to perform a
genome-wide over-expression screen. By identifying yeast genes
that modify FUS/TLS toxicity, we hoped to identify pathways or
proteins that would illuminate pathogenic mechanisms. We
screened an over-expression library containing a collection of
yeast open reading frames, fully sequenced and placed under the
control of a galactose-inducible promoter. A total of 5,535 genes
are covered in this library (representing 95% of the yeast genome).
We transformed each of the 5,535 genes into the yeast strain
expressing the moderately toxic one copy of FUS/TLS (untagged
FUS/TLS integrated into the yeast genome at the HIS3 locus) and
selected for those that suppress FUS/TLS toxicity upon over-
expression. All of the positive over-expression plasmids were
retransformed into a fresh yeast strain and validated for their
suppressive effects. Surprisingly, after three rounds of retesting,
only a handful of yeast genes could suppress FUS/TLS toxicity, all
of which are listed in the Table 1. FUS expression is very toxic in
yeast, and the identified suppressors do not completely abolish the
effect of FUS on yeast growth. As observed for a similar screen in a
yeast alpha-synuclein toxicity model [26], several transcription
factors that down-regulate the GAL1 promoter activity also
suppress the toxicity of FUS/TLS (Table 1, bottom section). These
modifiers were not specific to FUS/TLS; they also suppress other
toxic proteins expressed under GAL1 promoter control, such as
TDP-43.
All the FUS/TLS-specific suppressors are DNA/RNA binding
proteins (Table 1, top section; and Figure 6A), including ECM32,
SBP1, SKO1, and VHR1. As shown in Figure 6B, FUS/TLS
protein level was not altered by over-expression of these four
genetic modifiers, supporting the hypothesis that the rescue is not
mediated by reducing the amount of FUS/TLS.
ECM32 (also called MTT1) encodes a DNA-dependent
ATPase/DNA helicase belonging to the Dna2p- and Nam7p-
like family of helicases that are involved in modulating
translation termination [34]. (Interestingly, we also detected
NAM8, an RNA binding protein that interacts genetically with
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PLoS Biology | www.plosbiology.org 6 April 2011 | Volume 9 | Issue 4 | e1001052NAM7 in yeast, as a suppressor of FUS toxicity. We include it on
our list, but we are uncertain of its specificity; it appears as a
suppressor in many screens and may cause some nonspecific
downregulation of the GAL1 promoter. Yeast NAM7,w h i c hi s
sometimes called yeast UPF1, is a homologue of ECM32, but
neither we nor Sun et al. [30] found NAM7 as a strong
Figure 4. Deletion of arginine methyl transferase does not rescue FUS/TLS toxicity nor change its localization. (A) Empty vector and N-
terminus GFP-tagged FUS/TLS on pYES2CT were transformed into yeast arginine methyl transferase deletion strain rmt1D, rmt2D, and its isogenic
wild type BY4743 (WT). Spotting assay was performed to observe toxicity from the above yeast strains. (B) Expression of the proteins from above
strains was induced by 2% galactose for 6 h. Localization and aggregation of the protein was visualized by fluorescence microscopy.
doi:10.1371/journal.pbio.1001052.g004
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to induce a nonsense suppression phenotype in a wild-type yeast
strain, and the ECM32 gene product has been shown to interact
with translation termination factors and is localized to polysomes
[34]. ECM32 is homologous to the human gene hUPF1, which
encodes a protein previously shown to function in both mRNA
turnover and translation termination, and which can be found in
P-bodies, cytoplasmic granules that are sites of mRNA
Figure 5. FUS_plus and FUS_switch promote nuclear localization and lower toxicity of FUS/TLS. (A) GFP was fused with the nuclear
localization signal of FUS/TLS (GFP_FUS) and Hrp1 (GFP_Hrp1) as shown in top part of (A). Expression of protein from yeast containing above
constructs was induced by 2% galactose for 6 h. Localization and aggregation of protein was visualized by fluorescence microscopy. (B) Hrp1 NLS
was added to the c-terminal end of FUS/TLS (FUS_plus) or was used to replace nuclear localization signal of FUS/TLS (FUS_switch), as shown on part
top of (B). Protein expression from yeast containing above constructs was induced by 0.1% galactose for 6 h. Protein localization and aggregation
was visualized by fluorescence microscopy. (C) The same yeast strains were grown in raffinose medium and 0.1% galactose medium. Cell growth was
monitored using a Bioscreen machine for 2 d at 30uC. Typically, at least 10 replicates were done for each.
doi:10.1371/journal.pbio.1001052.g005
A Yeast Model of FUS/TLS-Dependent Cytotoxicity
PLoS Biology | www.plosbiology.org 8 April 2011 | Volume 9 | Issue 4 | e1001052sequestration and turnover, including nonsense-mediated decay
(NMD).
SBP1 encodes a putative RNA binding protein that is involved
in translational repression and is also found in cytoplasmic
P-bodies [35].
SKO1 encodes a basic leucine zipper transcription factor of the
ATF/CREB family, which forms a complex with Tup1p and
Ssn6p that acts as a repressor of transcription. In response to
osmotic and oxidative stress, this complex can be converted into
an activator that recruits SAGA and SWI/SNF [36].
Table 1. Yeast genes rescuing the toxicity of human FUS/TLS when over-expressed.
Gene Function Human Homologue Function of Human Homologue
Genes suppressing FUS/TLS toxicity
when over-expressed
ECM32 Member of the Dna2p- and Nam7p-like
family of RNA helicases; involved in
translation termination
UPF1 Nuclear mRNA export, mRNA surveillance, nonsense-
mediated mRNA decay, Staufen1-mediated mRNA
decay, replication-dependent histone mRNA decay,
DNA synthesis and repair, telomere maintenance
NAM8* RNA binding protein; component of
the U1 snRNP protein complex
involved in mRNA maturation
TRNAU1AP Unknown; contains a putative RNA-binding domain
SBP1 Putative RNA binding protein; localizes
to P-bodies and associates with snRNPs
RBM14 Nuclear receptor coactivator
SKO1 Transcription factor of the ATF/CREB family None
VHR1 Transcriptional activator None
Genes regulating GAL1 promoter/
general gene expression
MBP1 Transcription factor None
MIG1 Multicopy inhibitor of GAL gene expression None
MIG3 Transcriptional repressor
REG1 Negative regulator of glucose-repressible
genes
None
ZDS1 Transcriptional silencing None
ZDS2 Transcriptional silencing None
*Identified in a number of other yeast suppressor screens. May affect GAL-driven gene expression.
doi:10.1371/journal.pbio.1001052.t001
Figure 6. Expression of ECM32, SBP1, SKO1, and VHR1 rescues FUS/TLS toxicity. (A) ECM32, SBP1, SKO1, and VHR1 were individually
transformed into 1X FUS strain. Spotting assay was performed to observe toxicity of yeast containing the above constructs. (B) Protein expression was
induced by 2% galactose for 6 h from above yeast strains. Western blot analysis was performed using an antibody against FUS/TLS. PGK1 is shown as
a control of protein loading.
doi:10.1371/journal.pbio.1001052.g006
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PLoS Biology | www.plosbiology.org 9 April 2011 | Volume 9 | Issue 4 | e1001052VHR1 is a transcriptional activator that is required for the
vitamin H–responsive element (VHRE) mediated induction of
VHT1 (Vitamin H transporter) and BIO5 (biotin biosynthesis
intermediate transporter) in response to low biotin concentrations
[37]. In humans, biotin deficiency leads to a variety of clinical
abnormalities, including neurological disorders, growth retarda-
tion, and dermal abnormalities [38].
All of these genes were identified by Sun et al. in an
independent screen for suppressors in a similar yeast model for
FUS/TLS-dependent proteotoxicity [30]. Differences between
results of the two screens probably reflect differences in the
protocol of the initial pass, plus differences in stringency in
retesting.
Of the genetic modifiers identified from our screen, ECM32 is
the only gene that is capable of rescuing toxicity of yeast strains
integrated with both one copy (Figure 7A) and two copies of FUS
(Figure 7B). The other suppressors only rescue toxicity of 1XFUS
(unpublished data). We therefore turned our attention to the
human homologues of this protein.
hUPF1, a Human Homolog of ECM32, Rescues Toxicity of
FUS/TLS
Based on sequence similarity (,30% identity and ,50%
similarity in the helicase domain), hUPF1, a gene playing an
important role in the pathway of nonsense-mediated decay
(NMD), is the closest human homolog of ECM32 [39]. Because
of this homology, we hypothesized that the toxicity of FUS/TLS
may be rescued by yeast expression of hUPF1. The full-length
hUPF1 gene was cloned into a yeast expression vector and tested
on the toxicity of FUS/TLS. Over-expression of hUPF1 rescues
the toxicity of both 1XFUS and 2XFUS (Figure 7A and B). To
check for possible direct interaction between hUPF1 and FUS/
TLS, we co-expressed red fluorescent protein-tagged hUPF1 and
GFP-tagged FUS/TLS. hUPF1 is expressed mainly in the cytosol
in yeast but does not co-localize with FUS/TLS (Figure 7C),
suggesting the rescue effect by hUPF1 might be indirect. However,
more data are needed to rule out possible over-expression artifacts.
Next, we investigated whether the expression of hUPF2, another
nonsense-mediated decay pathway gene whose protein product is
known to form a complex with the UPF1 protein, might also
rescue FUS toxicity in yeast, and found that it did, to an equal
extent as that of hUPF1 (Figure 7). However, over-expression of
human UPF3, another protein known to interact with UPF1,
showed only moderate rescue compared to hUPF1 and hUPF2
(suppression of toxicity of 1XFUS but not of 2XFUS). We then
examined the expression of the next closest human homologue of
ECM32, IGHMBP2 (,25% identity), a ribosome-associated
helicase implicated in DNA replication, pre-mRNA splicing, and
transcription [40]. Mutations in IGHMBP2 cause distal spinal
muscular atrophy type 1, a neuromuscular disorder [40].
However, expression of hIGHMBP2 in yeast did not rescue
FUS/TLS toxicity (unpublished data).
To check the possible effect of ECM32, hUPF1, and hUPF2 on
the protein expression level or aggregation of FUS/TLS, Western
blots and indirect immunofluorescence using FUS/TLS antibody
were performed. Neither protein levels (Figure 8A) nor localization
or aggregation of FUS/TLS (Figure 8B) was modified by over-
expression of ECM32, hUPF1,o rhUPF2.
hUPF1 has an N-terminal hUPF2 binding domain and a C-
terminal ATPase/Helicase domain. To determine whether the
rescue of FUS/TLS toxicity requires both domains, we tested the
constructs expressing only the hUPF2 binding domain (hUPF1-
418) or the ATPase/Helicase domain (hUPF419-1118). As shown
in Figure 8C, neither domain rescues the toxicity of FUS/TLS to
the extent that the full-length wild type protein rescues. To
further test whether ATPase/Helicase activity is required for the
rescue, we checked the full-length protein with ATPase/Helicase
partially inactivated by a point mutation (R844C) [41] and found
that FUS/TLS toxicity cannot be fully rescued when ATPase/
Helicase activity of hUPF1 is inhibited. It is noteworthy that
hUPF1(R844C) still has 60% of the activity of wild-type hUPF1
[41], so it is quite possible that fully inactivated hUPF1 would not
rescue at all. These data suggest that both domains of hUPF1 and
functional ATPase/Helicase activity are required for its rescue of
FUS/TLS toxicity.
CYH2 But Not MER2 Pre-mRNA Was Accumulated When
FUS Was Over-expressed
To prevent the potential accumulation of deleterious nonsense
fragments of polypeptides in the cytoplasm, mRNAs that retain an
intron containing an in-frame nonsense codon are usually
degraded by the nonsense-mediated decay (NMD) pathway. It is
long established that CYH2 and MER2 pre-mRNA are among the
substrates of this pathway in yeast. These pre-mRNAs are
accumulated 2- to 5-fold when the NMD pathway is deficient
[42]. To check the potential effects of FUS expression on the
NMD pathway, qRT-PCR was utilized to determine CYH2 and
MER2 pre-mRNA levels in 1XFUS yeast, and in its suppressor
strains. As shown in Figure 9A, CYH2 pre-mRNA was increased
about 2-fold when FUS is over-expressed, and co-expression of its
suppressor hUPF1 brought CYH2 pre-mRNA back to the wild
type level; however, co-expression of another suppressor, ECM32,
did not, suggesting that these two suppressors may rescue FUS
toxicity through different mechanisms.
In contrast to CYH2, over-expression of FUS and co-expression
of its suppressors did not change MER2 pre-mRNA levels
(Figure 9B). Since MER2 pre-mRNA is another substrate of the
NMD pathway, this result implies that accumulation of CYH2 pre-
mRNA by FUS over-expression is not through its direct effect on
the NMD pathway but through an effect on one or more
additional pathways of mRNA quality control. Possibly, the
restoration of the level of CYH2 pre-mRNA to normal by hUPF1
expression in the 1XFUS strain also does not reflect hUPF1
function in NMD.
Discussion
Many essential cellular functions are conserved in the simple
eukaryote yeast. Studies from this organism have provided
valuable information for our understanding of many critical
cellular functions, including cell cycle regulation, DNA replication,
RNA synthesis and processing, protein synthesis, protein traffick-
ing, and signal transduction. This simple system has also been
utilized to study functions of proteins involved in human diseases,
including neurodegenerative diseases. Although a yeast model
usually cannot recapitulate all of the cellular processes in human
cells, it has proven to capture key aspects of molecular pathology
for several neurodegenerative disorders [27]. With its ease of high-
throughput manipulations for both genetics and biochemistry, the
yeast model organism provides invaluable tools for studying
molecular mechanisms of human diseases. For those human
proteins for which yeast cytotoxicity models are available, toxicity
from each protein is usually quite different. Genetic modifiers
identified from those yeast models usually do not overlap,
supporting the use of yeast models for studying functions of
human proteins specifically.
In this article, we report a yeast model of FUS/TLS-associated
proteotoxicity when the protein is mislocalized to the cytoplasm.
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PLoS Biology | www.plosbiology.org 10 April 2011 | Volume 9 | Issue 4 | e1001052The model faithfully recapitulates the cytosolic aggregation and
cytotoxicity observed in spinal motor neurons in the human
disease. We exploited this model to test various hypotheses about
FUS-mediated cytotoxicity. Comparison of the aggregates isolated
from the model with those from yeast models of huntingtin toxicity
and TDP-43 toxicity showed that they differed from the former
but were similar to the latter; two yeast genes known to affect
huntingtin aggregation when over-expressed also failed to affect
FUS/TLS localization or aggregation. Clustering of fALS-
associated FUS mutations in regions of potential arginine
dimethylation prompted us to investigate the effects of deletion
of either of the major yeast arginine methyltransferases on
Figure 7. hUPF1 rescues FUS/TLS toxicity. hUPF1 and hUPF2 were cloned into yeast expression vector pYES2CT. (A) The constructs were
transformed into 1XFUS (one copy of FUS/TLS integrated at HIS locus). Spotting assay was performed to check the rescue of toxicity by hUPF1 and
hUPF2. Empty vector and ECM32 construct from library screen were used as negative and positive controls. (B) The above constructs were
transformed into 2XFUS (two copies of FUS/TLS integrated at HIS locus and TRP locus, respectively). Spotting assay was performed to check the
rescue of toxicity by hUPF1 and hUPF2. (C) GFP tagged FUS/TLS (pYES2CT/GFP-FUS) and RFP tagged hUPF1 (pRSGal1hUPF1-DsRed) were transformed
into yeast. Protein expression was induced by 2% galactose for 6 h and visualized by fluorescence microcopy.
doi:10.1371/journal.pbio.1001052.g007
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deletions nor introduction of known chemical inhibitors of yeast
arginine methyltransferase activity had any effect on these
properties. Over-expression of the major yeast and human
arginine methyltransferaaes also failed to modulate FUS/TLS
toxicity in yeast. However, we have no data at present to indicate
that human FUS/TLS is a substrate for the yeast arginine
methyltransferases (even though they are close homologues of the
major human arginine methyltransferase, PRMT1), so we cannot
conclude from this experiment that arginine methylation may play
no role in FUS/TLS toxicity in mammalian cells. It does not seem
to be a major factor in toxicity in yeast.
Initially, the observation that both WT and mutant FUS
localized to the cytoplasm and were equally toxic was unexpected.
However, recent work on the C-terminal FUS mutations provides
a satisfying explanation [19]. These mutations prevent the nuclear
import of FUS, increasing cytoplasmic accumulation in stress
granules and, eventually, producing toxic and insoluble aggre-
gates. FUS uses an unusual nuclear localization signal (NLS) of the
bPY-type. Although yeast has this same bPY-type nuclear
localization system, divergence in the recognition signal would
cause toxic mislocalization of even the WT FUS protein in yeast.
Indeed, when we compared the ability of the WT FUS NLS signal
and a known functional yeast bPY-type NLS to drive a GFP
reporter into the nucleus, the FUS signal was nonfunctional. Next,
we reasoned that if cytoplasmic mislocalization of FUS was
responsible for increased toxicity, then restoring nuclear localiza-
tion with a recognition sequence that does function in yeast should
reduce toxicity. This proved to be correct. Thus, our work
provides an independent validation of Haass’ recent model [19],
recapitulating the observation that cytoplasmic mislocalization is
important in the toxicity of FUS. This mechanistic link between
mutations and toxicity is in contrast to TDP-43, where ALS
mutations increase aggregation in vitro (as opposed to transport)
and enhance toxicity in yeast [28]. In agreement, the accompa-
nying manuscript demonstrates that FUS mutations do not alter
aggregation or toxicity [30]. The lack of an effect of ALS
mutations in yeast separates two aspects of FUS pathology—(1)
mislocalization and (2) cytoplasmic toxicity. Since the NLS is
nonfunctional in yeast, our system models the cytoplasmic-
dependent toxicity, but not the mechanism of mislocalization
itself. Because the link between mislocalization and ALS mutants
Figure 8. Rescue of FUS/TLS toxicity requires full length hUPF1, and rescue is not mediated by decrease in FUS/TLS protein level or
inclusion formation of the protein. (A) Protein expression was induced by 2% galactose for 6 h in 1XFUS strain expressing hUPF1, hUPF2, or
ECM32. Western blot was performed using an antibody against FUS/TLS to check the expression of FUS/TLS. PGK1 is shown as a control of protein
loading; (B) the same yeast cells were also subject to indirect immunofluorescence staining using primary antibody against FUS/TLS, and secondary
antibody conjugated with fluorescein. Nuclear DNA was stained with DAPI. (C) Different domains of hUPF1 were cloned into a yeast expression vector
and transformed into 1XFUS strain. Spotting assay was performed to check rescue of the toxicity. hUPF1-418, hUPF2 binding domain; hUPF419-1118,
ATPase/Helicase domain; hUPF1R843C, inactivated ATPase/Helicase by arginine to cysteine mutation at residue of 843 in the full length FUS/TLS.
doi:10.1371/journal.pbio.1001052.g008
A Yeast Model of FUS/TLS-Dependent Cytotoxicity
PLoS Biology | www.plosbiology.org 12 April 2011 | Volume 9 | Issue 4 | e1001052Figure 9. Yeast CYH2 but not MER2 pre-mRNA was accumulated when FUS is over-expressed. Cells were grown in raffinose medium to
early log phase. Protein expression was induced by 2% galactose for 6 h in 1XFUS strain expressing empty vector (1XFUS), human UPF1 (+hUPF1), or
ECM32 (+ECM32). CYH2 pre-mRNA (A) and MER2 pre-mRNA level (B) were determined by qRT-PCR using 18sRNA as an internal control. Pre-mRNA in
wild type yeast cell without integration of FUS (WT) was normalized to 1.
doi:10.1371/journal.pbio.1001052.g009
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tion not as a liability but rather as a strength, in that it allows us to
focus on toxicity itself.
We also expressed a series of FUS/TLS constructs with various
domains deleted and found that the C-terminal region of the
protein was necessary but not sufficient for toxicity. In an
independent, more detailed study using a similar yeast model of
FUS/TLS toxicity, Sun et al. [30] conclude that, in contrast to
TDP-43, determinants in both the N- and C-terminal regions of
FUS are required to couple aggregation to toxicity in vivo and for
spontaneous aggregation in vitro, suggesting that FUS aggregates
by a mechanism distinct from that of TDP-43. They also find that
FUS is intrinsically aggregation-prone and that the aggregates
formed by purified FUS in vitro closely resemble the aggregates
observed in affected neurons in human disease.
Some of the aggregates formed by the various deletion
constructs appeared to differ from one another slightly when
viewed microscopically. We have not yet characterized the nature
of the aggregation in any of these cases, but if different
morphological aggregates are indeed toxic and similar-looking
aggregates are not always toxic, as we in fact observe, our data
lend support to the conclusion that aggregation and toxicity may
not be tightly coupled in this system.
Using a yeast over-expression library screen, we identified five
yeast genes that, when over-expressed, rescue the toxicity of FUS/
TLS. Strikingly, all five genetic modifiers are, like FUS, DNA/
RNA binding proteins. We have compared genetic modifiers from
other yeast models and found that these five genes are not
identified as suppressors in other yeast models for neurodegener-
ative diseases, including Parkinson’s disease (over-expression of a-
synuclein [25]), TDP-43-dependent ALS (over-expression of wild-
type TDP-43 [28]), and Huntington’s disease (over-expression of
polyQ-expanded huntingtin [24]), indicating that they are specific
to FUS/TLS. We also note that genetic screens from other yeast
models usually identify many more genetic modifiers. The very
limited number of hits from our FUS/TLS yeast model suggests
that the toxicity of FUS/TLS may stem from its effect on a limited
number of cellular functions. Our screening results are similar to
results obtained independently by Sun et al. [30], who found 23
over-expression suppressors (including all of the genes we
identified) and also carried out a screen for yeast genes that
modify toxicity when deleted. Further, they provide compelling
evidence that stress granules and P-bodies are likely to be involved
in FUS/TLS effects in yeast. We have also found a correlation
between mutant FUS/TLS and stress granules that may be
relevant to ALS pathogenesis [20].
Most importantly, we found that expression of hUPF1 (or of its
physical interacting partner hUPF2 and, to a lesser extent, hUPF3)
rescues FUS/TLS toxicity. Among other roles, hUPF1 plays a very
important function in mRNA quality control, including nonsense-
mediated decay (NMD), a critical cellular mechanism of mRNA
surveillance that functions to detect nonsense mutations and
prevent the expression of truncated or erroneous proteins [43]. It
has been proposed that a principal event underlying neurodegen-
eration occurs when cytotoxic, truncated proteins are expressed
from normally degraded nonsense-containing RNAs and pseudo-
gene transcripts [44]. Our finding that hUPF1 and hUPF2 rescue
the toxicity of FUS/TLS is broadly consistent with this hypothesis;
however, our results from examination of the level of specific
NMD mRNA substrates (see below) suggest that NMD cannot be
the sole RNA pathway affected by FUS or its suppressors in yeast.
Our results do suggest the possibility that disruption of some part
of the RNA quality control process might be related to the toxicity
mechanism of FUS/TLS.
Because ECM32, hUPF1,o rhUPF2 expression all rescue FUS
toxicity without dissolving the cytosolic aggregates or changing the
expression level of FUS or its mislocalization, it is likely that
toxicity involves disruption of some essential cellular function that
is either restored or compensated for by the introduction of these
genes. One possibility is that FUS over-expression sequesters RNA
and/or protein molecules involved in nonsense-mediated decay,
which is an essential function in yeast. Yeast contains no FUS
homologue, but many of the other proteins important for RNA
quality control are conserved between S. cerevisiae and humans.
To check the possible direct effect of FUS on the NMD pathway,
we determined pre-mRNA levels of CYH2 and MER2, which are
among the reported substrates of the NMD pathway in yeast. If this
pathway is impaired by FUS over-expression, it is then expected
that both pre-mRNAs would be accumulated. However, only CYH2
pre-mRNA is increased by FUS expression in our assay, suggesting
that FUS may interfere with other RNA quality control systems,
ratherthan exerting a directeffect ontheNMDpathway.It is worth
mentioning that CYH2 pre-mRNA was accumulated to a much
higher level than MER2 in our assay (5-fold versus 2-fold;
unpublished data); this may help to explain no detected accumu-
lation of MER2 pre-mRNA when FUS is over-expressed.
In addition, co-expression of hUPF1 and yeast ECM32,t w o
suppressors of FUS toxicity, had different effects on the accumulated
CYH2 pre-mRNA level caused by over-expression of FUS. Together
with their different rescuing effects on other yeast neurodegenerative
disease models, these data suggest that hUPF1 and ECM32 may
rescue FUS toxicity through different mechanisms.
It is important to emphasize that we are not claiming that this is a
yeast model of a human disease. It is a model for the cytotoxicity of a
human protein whose mislocalization to the cytosol causes a
devastating neurologic disorder. It appears to recreate the salient
features of that part of the pathology: cytosolic localization,
aggregation in stress granules, and cell death. It has allowed us to
determine the parts of the protein essential for toxicity, to test
hypotheses about the factors responsible for localization, and to
identify suppressor genes in both the yeast and human genome. We
believe that the fact that wild type and mutant are both toxic in this
model is not a failing of the model. Both wild-type and mutant are
mislocalized to the same extent in yeast because the FUS nuclear
localization signal, where the mutations occur, is not efficient in the
microbe, and so if the neurotoxicity of the mutants is entirely due to
their mislocalization, as has been hypothesized by others, then the
wild type protein should also be toxic in our model, exactlyas observed.
In summary, our yeast model recapitulates multiple features of
disease-causing mutant protein FUS/TLS pathology, including
aggregation, cytosolic localization, and toxicity, which should make
it valuable for studying the function and mechanism of toxicity of
this protein in human neurodegenerative disorders. In addition, our
model is amenable to high-throughput small molecule screens to
identify compounds that suppress FUS/TLS toxicity. Like TDP-43,
which saw a number of cell culture and animal models follow its
identification as an ALS/FTLD protein, we envisage a similar
trajectory for FUS/TLS. By importing our yeast findings into
mammalian cell culture and neuronal systems, we anticipate
creating a yeast discovery/mammalian confirmation paradigm that
will yield critical insights into FUS/TLS pathobiology and
potentially provide therapeutic targets or pathways for exploitation.
Materials and Methods
Plasmids
N-terminal GFP-tagged FUS (pYES2/GFP-FUS): GFP tagged
FUS gene was amplified from pDEST53/FUS by PCR using
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GATTATACCC-39, and reverse primer 59-ATTAGCCGTCTA-
GATTAATACGGCCTCTCCCTGC-39, and sub-cloned into
KpnI and XbaI sites of yeast expression vector pYES2CT
(Invitrogen).
Entry clone of FUS (pDONR221/FUS): full-length FUS gene
in destination vector pDEST53/FUS was transferred into
Gateway entry vector pDONR221 (Invitrogen) using BP reaction
(Invitrogen).
Yeast expression and integration constructs of FUS: A gateway
LR reaction (Invitrogen) was used to shuttle FUS gene from entry
clone into gateway compatible yeast expression vectors (pAG
vectors, www.addgene.org/yeast_gateway).
Yeast expression vectors of UPF1 (pYES2/UPF1) and UPF2
(pYES2/UPF2): UPF1 and UPF2 were amplified by PCR. The
genes were generously supplied by Dr. Lynne Maquat of
Rochester University School of Medicine and Dentistry. UPF1
was sub-cloned into BamHI and XhoI sites of pYES2CT, and
UPF2 was sub-cloned into NotI and XhoI sites of pYES2CT.
GFP and FUS NLS fusion constructs were generated using an
overlap PCR strategy. GFP and HRP1 or FUS/TLS NLSs were
PCR amplified in the first step. In the second step, GFP was
combined with either HRP1 or FUS/TLS NLS PCR using the
GFP forward primer and HRP1 or FUS/TLS reverse primer.
This product was cloned into Pst1/Spe1 sites in the pRS424Gal1
vector. For ‘‘FUS_plus’’ or ‘‘FUS_switch’’ constructs, the first
PCR step amplified FUS or FUS lacking the C-terminal PY NLS
and the Hrp1 NLS. Full-length FUS or NLS-lacking FUS were
combined with the Hrp1 NLS PCR product and amplified in a
second reaction containing a FUS forward primer and HRP1
reverse primer. This final product was cloned into pRS424Gal1.
Oligo sequences are available upon request.
All constructs made for this study were confirmed by
sequencing.
Yeast Strains, Media, and Growth Conditions
1XFUS integration strain was generated by linearizing
pAG303GAL1FUS with NheI, and followed by transformation
into W303a strain (MATa can1-100, his3-11,15, leu2-3,112, trp1-
1, ura3-1, ade2-1).
2XFUS integration strain was generated by linearizing
pAG303GAL1FUS with NheI, and pAG304GAL1FUS with
BstZ17I, followed by transformation into W303a strain (MATa
can1-100, his3-11,15, leu2-3,112, trp1-1, ura3-1, ade2-1). Both
1XFUS and 2XFUS strains were confirmed by PCR.
Htt25 and Htt103 strains: N-terminal fragments of huntingtin
with 23 glutamine repeats or 103 glutamine repeats, respectively,
were integrated into HIS locus of W303 strain.
rmt1D, rmt2D, hsp104D, and rnq1D strains are homozygous
diploid from the yeast deletion collection (Research Genetics).
BY4743 is its isogenic wild type.
Synthetic media lacking uracil (Ura-), histidine (His-), histidine
and tryptophan (His-Trp-), histidine and uracil (His-Ura-), and
containing 2% glucose, raffinose, or galactose were used for the
respective yeast strains.
Yeast cells were grown in 30u incubators (plate) or 30u shakers
(liquid medium) unless specially mentioned.
Growth curves of FUS NLS strains were monitored using
Bioscreen (www.bioscreen.fi). Yeast strains were pre-grown in 2%
raffinose, diluted to an OD600 of 0.01, and induced with 0.1%
galactose for 2 d with OD measurements taken every 10 min. Raw
data were averaged among triplicates and OD600 plotted over
time. Three independent experiments were performed and a
representative shown.
Yeast Over-expression Library
The over-expression library is the FLEXGene Collection [45].
Additional information about the yeast FLEXGene Collection
is available at http://plasmid.med.harvard.edu/PLASMID/Get
Collection.do?collectionName=HIP%20FLEXGene%20Saccharo
myces%20cerevisiae%20%28yeast%29%20ORF%20collection%
20%28pBY011%20expression%20vector%29. For the expression
screen, the clones were transferred into a galactose-inducible
expression plasmid (pBY011; CEN, URA3,A m p
R) using the
Gateway technology (Invitrogen).
Yeast Transformation
Yeast expression constructs were transformed using standard
PEG/lithium acetate method. Briefly, cells from one-milliliter
overnight culture plus DNA construct was mixed with transfor-
mation buffer (80 ml 50% PEG3350, 10 ml 1M DTT, and 10 ml
2M LiAC), followed by incubation at 42u waterbath for 45 min
(with occasional mix during the incubation). Cells were then
spread onto respective dropout plates and grown at 30u for 3–4 d.
Serial Dilution and Spotting
Yeast cells were grown overnight to mid-log phase. Cultures
were then normalized to OD600 =5.0, and 106serially diluted
and spotted onto the respective dropout plates containing 2%
glucose or galactose.
Immunobotting
Yeast crude extract was subjected SDS-PAGE, and protein was
transferred onto PVDF membrane (Millipore), followed by 30 min
incubation with superblock (Thermosci). PVDF membrane was
then hybridized with primary antibody for 2 h at RT, followed by
wash with 1XPBS 5 times (10 min each), incubation with
secondary antibody conjugated with alkaline phosphatase (Pro-
mega) for 2 h, and 5610 min wash with 1XPBS. The membrane
was finally developed with one-step NBT/BCIP solution (Thermo
scientific). The anti-FUS antibody (Abcam) and anti-PGK1
(Invitrogen) were used at a dilution of 1:1,000. The AP conjugated
secondary antibody was used at dilution of 1:10,000. For FUS
NLS fusion experiments, cells were induced with 0.1% galactose
for 6 h, after which they were fixed and visualized with anti-FUS
antibody as described above.
Fluorescence Microcopy of GFP-Tagged Protein
Cells were grown in selective raffinose medium to early log phase,
and 2% galactose was then added into the medium for 6 h to induce
the expression of the protein. Cells were harvested and fixed 1 h on
ice in freshly made fixation buffer (50 mM Kpi pH 6.5; 1 mM
MgCl2, and 4% formaldehyde). Cells were then washed 3 times with
1XPBS before viewing by fluorescence microscopy.
To visualize the nucleus, following the PBS washes, cells were
incubated in PBS containing DAPI (1:1,000) for 30 min. Cells
were finally washed 3 times with 1XPBS before viewing by
fluorescence microscopy.
Filter Retardation Assay
Yeast cells were grown in raffinose medium to early log phase.
Expression of protein was induced for 6 h by adding 2% galactose
into the medium. Cells were harvested and treated with zymolase,
and the spheroblast was broken by vortex, and protein extract was
prepared by collecting the supernatant (centrifuge 5,000 rpm,
5 min). Protein concentration was determined by Bradford assay.
2% of SDS was added to the protein sample before the sample was
boiled for 5 min. 10-fold dilutions of protein samples was prepared
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scientific) with cellulose acetate membrane (pore size 2 m; What-
man). Vacuum was applied and all the liquid was sucked through
the manifold. After washing 5 times with 0.2% SDS, the manifold
was dissembled carefully, and cellulose acetated membrane was
used for Western blotting to detect protein.
Indirect Immunofluorescence of Yeast Cells
Indirect immunofluorescence of yeast cells with FUS antibody was
adapted from chapter 40 of ‘‘Guide to Yeast Genetics and Molecular
Biology.’’ Yeast cells were grown to early log phase in the selective
raffinose medium, and expression of the interested protein was
induced for 6 h by 2% galactose. Cells were fixed in freshly made
fixation buffer (50 mM Kpi pH 6.5, 1 mM MgCl2, and 4%
formaldehyde) for 2 h at room temperature. Cells were then washed
two times with PM buffer (0.1 M Kpi pH 7.5, 1 mM MgCl2) and
resuspended with PM buffer with protease inhibitors (Roche). Cells
were then treated with zymolase for 20 min. Spheroblasts were
harvested at 2,000 rpm and washed once with PM with protease
inhibitors.Cellswerethenspottedontopoly-l-lysinecoatedwellofthe
slide. We immersed the slide for 5 min each in methanol and acetone
(pre-cooled to 220uC). Cells were then blocked by PBS-block
(1XPBS, 1% dried milk, 0.1%BSA, 0.1% octyl glucoside) for 1 h,
followed by incubation with primary antibody (Abcam, 1:100
dilution), wash, incubation with secondary antibody conjugated with
fluorescein (Invitrogen, 1:100 dilution), and wash.
5 ml of mounting solution (Santa Cruz Biotech) was added to
each well, and cells were viewed using fluorescence microscope.
To visualize nucleus, DAPI (1:1,000) was included in the mounting
solution.
Yeast Over-expression Library Screen
One copy integrated FUS strain (1XFUS) was grown to early
log phase and washed with 0.1 M lithium acetate (LiAc) in TE
buffer. Cells were then resuspended in 0.1 M LiAC, and 35 mlo f
the resuspended cells was aliquoted into 96-well plates and
incubated at 30u for 30 min. 1 ml of yeast FLEXGene Collection
DNA (the Collection consists of vectors expressing each of 5,535
individual yeast genes, arrayed on 96-well plates; see [44]), and
125 ml transformation buffer (0.1 M Lithium Acetate, 10%
DMSO, 40% PEG3350) was then added to the plate, followed
by 30 min incubation at 30u, and 20 min heat shock at 42u. Cells
were pelleted and resuspended into 200 ml of synthetic Ura-
dropout medium, 10 ml of which was then inoculated into new
plate with 200 ml Ura- dropout medium in each well. Cells were
grown at 30uC for 2–3 d. All the liquid handling was done using
liquid handling robot (Tecan Freedom EVO).
Cells were mixed using 96-well plate vortexer (VWR), and
quadruply spotted onto Ura-Glucose and Ura-Galactose plates
using Singer RoToR Robot (Singer Instruments), followed by
incubation at 30u for 2–3 d. Colonies grown on galactose plates
were considered as putative suppressors.
After the whole library (5,535 genes) was screened, all the putative
suppressors were re-tested by re-transforming the corresponding
genes into 1XFUS strain. Those surviving the re-test are finally
confirmedbymanuallytransformingeachofthecorrespondinggenes
into 1XFUS stain, and phenotype was re-tested by serial dilution.
Pre-mRNA Analysis by qRT-PCR
Cells were grown in synthetic raffinose medium to early log
phase; expression of FUS and its suppressors (hUPF1 and ECM32)
were induced by 2% galactose for 6 h. Cells were harvested, and
total RNA was extracted using the standard hot acidic phenol
method (Current Protocols in Molecular Biology, Unit 13.12).
RNA was treated with DNase I (Promega) to remove the trace
contamination of genomic DNA before it was used for cDNA
synthesis. cDNA was synthesized using the superscript III
platinum two-step qRP-PCR kit (Invitrogen). qPCR was per-
formed on stepOnePlus real-time PCR system (Applied Biosys-
tems). The PCR mixture contained platinum Taq and SYBR
Green I (Invitrogen) and the corresponding primers: CYH2Pre
forward: 59-GTATCAAATGGTTGTAGAGAGCGC-39, CY-
H2Pre reverse: 59-TGTGGAAGTATCTCATACCAACC-39;
MER2Pre forward: 59- GAACAAGATGCTGCTACGAACG-
GT-39, MER2Pre reverse: 59- TGCCTGTAGCTGGAATCC-
GACTTT-39. mRNA levels were quantified and normalized to
that of 18sRNA, using primers: 18sRNA forward: 59- TTCTG-
GCTAACCTTGAGTCC-39, and 18sRNA reverse 59- AAA
ACG TCC TTG GCA AAT GC-39.
Supporting Information
Figure S1 Inclusion formation and toxicity of FUS/TLS in wild
type and mutant forms (H517Q and R521G) are comparable. (A)
Cells expressing GFP-FUS on pYES2CT vector in both wild type
and mutant forms (H517Q and R521G) were induced by 2%
galactose for 6 h. Cells were then fixed and viewed by fluorescence
microscopy. DAPI was used to stain the nucleus. (B) The same
cells were subjected to Western blot analysis using an antibody
against FUS/TLS. PGK1 is shown as a control of protein loading.
(C) The spotting assay was performed to observe toxicity from the
same yeast strains as above.
(TIF)
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